The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection.
about
Can routine neonatal circumcision help prevent human immunodeficiency virus transmission in the United States?Pre-donation screening of blood for transfusion transmissible infections: the gains and the pains - experience at a resource limited blood bankOversight and monitoring of blood safety in the United States.Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective.US NAT yield: where are we after 2 years?Molecular and contextual markers of hepatitis C virus and drug abuse.Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomesIncidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.Blood donor deferral policies across Europe and characteristics of men who have sex with men screened for human immunodeficiency virus in blood establishments: data from the European Men-who-have-sex-with-men Internet Survey (EMIS).Does recombinant human erythropoietin accelerate correction of post-ulcer-bleeding anaemia? A pilot study.Managing the microbiological safety of blood for transfusion: a US perspective.Probability of a false-negative HIV antibody test result during the window period: a tool for pre- and post-test counselling.Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe.Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections.A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors.Residual risk and waste in donated blood with pooled nucleic acid testing.Evaluation of LIAISON® XL system for HBsAg, and anti-HCV and anti-HIV/Ag p24.Contrasting HCV and HIV seroepidemiology in 11 years of blood donors screening in Brazil.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.Estimated risk of transfusion-transmitted viral infections in Spain.A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols.A probabilistic method for the estimation of residual risk in donated blood.Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations.Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies.Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.HIV seroconverting donors delay their return: screening test implications.The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.Detection of a healthy carrier of HCV with no evidence of antibodies for over four years.The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.Safety in transfusion medicine.False-negative testing errors in routine viral marker screening of blood donors. For the Retrovirus Epidemiology Donor Study.Recent Canadian experience with targeted hepatitis C virus lookback.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.Bayesian evaluation of the human immunodeficiency virus antibody screening strategy of duplicate enzyme-linked immunosorbent assay in Xuzhou Blood Center, China.Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.
P2860
Q24648641-1007CBE4-7518-4909-AC38-BEE97E13CAABQ33457204-FCFFE781-5479-4FC0-B5DF-3610A22FCA29Q33749419-3ED12DF2-E9B3-4B97-AD85-568F7924864AQ34299521-7C102328-BFCE-4039-8056-9310E9D246E8Q34830197-F32DE3A9-BE41-448C-83C7-889E2ABEC4E2Q35660841-A6DCE138-735A-473F-8E92-1F6B13215504Q36058580-7A72A00E-4205-4D03-A493-FE0CCEE95FCEQ36078723-11ED47C0-188F-4907-A014-2D9DC3E57AA6Q36252455-7983D084-7036-4AC3-B6BC-39EFCDA8F4FAQ36367719-ABB02928-8F2D-40F6-B698-5F806B08CE6FQ36474318-35ED9EBD-F3E9-4172-A742-A21177FF838AQ37590313-1A9A6113-77E8-4C18-87A9-869CB9FD2E06Q38230641-22D9418D-4314-4297-A865-ACC5E3849662Q38454850-A3BAF41D-3A55-42DC-8EC9-C5A269279335Q39131395-B90446CA-D9BD-4167-8C78-B4D62C2A248DQ39137413-B560F204-8E54-4A97-9ECE-AA6FD6C907D3Q39527094-93CBDB12-EA45-45B5-A903-8B2C2A78DB4CQ39550531-99F6C132-3A94-409D-BD8A-8A361970E429Q40194957-54216732-A1CF-4135-AC2A-D9681D7D98E6Q40383406-9D0FFBF7-D999-4C59-825E-1A5F1901F422Q40519030-206EBA78-AA5F-49F0-B88E-4A7760E39FE6Q40572754-25CBF768-589E-443F-A5B8-CBCDCB9E2BFEQ40611312-3F0E3610-D14D-4E62-AD03-0D455605A3E2Q40622701-6B459AD5-338C-4CC1-BEEB-D60F270D75E5Q40626774-E64C8DD5-295A-4C19-94DD-CA5071B7F3E5Q40741047-8108DCE2-F841-487E-835F-10BFE741B49EQ42221214-C08DB594-53D0-4987-B108-C792417719FFQ42863755-27264582-3DB5-4537-9C87-034B4EDD0C37Q42994597-E34AB390-C922-4132-BEC0-D4E5983B3BC1Q43036225-0D7C9B1F-D2C8-4686-9FB8-F432BC64F86FQ43038339-66FD4B4F-E389-40AA-A541-611589E5CC12Q43041881-C672C01A-4CAD-42E4-9C33-EF17CA9333A2Q43047994-FE50E293-65B9-450D-8838-85C417ADCE72Q43048511-43FF7BC7-CB9A-4D84-BBF8-67186E931764Q43198151-49E9656E-9CC5-48DF-BC3D-02972DEC477DQ43987669-29B6374D-40C2-4965-B9FA-4E9E1DB7F2DDQ44747535-04C3A0C2-0158-4FD3-9C6E-5E8F53A2E51EQ44931522-2E3B00A6-D24F-4E82-B1C0-6922624545D6Q45372714-91050872-3C18-44EA-B6EB-C9DAD8D0885EQ45672786-BE3FD8F2-ACD0-4E1C-B4AC-914A64B50170
P2860
The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The incidence/window period mo ...... d hepatitis C virus infection.
@en
type
label
The incidence/window period mo ...... d hepatitis C virus infection.
@en
prefLabel
The incidence/window period mo ...... d hepatitis C virus infection.
@en
P2093
P1476
The incidence/window period mo ...... d hepatitis C virus infection.
@en
P2093
Kleinman S
Korelitz JJ
Schreiber GB
P304
P356
10.1053/TMRV.1997.0110155
P577
1997-07-01T00:00:00Z